Barcelona, ​​July 2026 – Catalonia.health has completed the first edition of the IMPULS program, a business growth initiative for health companies developed with the support of ACCIÓ.

On July 7, Tech Barcelona's headquarters hosted a new training capsule from I4KIDS, the pediatric innovation hub coordinated by Hospital Sant Joan de Déu, organized in collaboration with Catalonia.health. The session brought together startup leaders, researchers and health professionals to discuss financing, regulation and international expansion in the field of pediatric health.

The company, a member of Catalonia.health, has obtained the CE marking for its surgical robotic system, a milestone that opens the door to its commercialization on the European market and marks the beginning of a new stage of growth.

The Catalonia.health barbecue celebrates its eleventh edition with 600 attendees and reaffirms itself as the networking space for Catalonia's health ecosystem

fetaLife Technologies, a spin-off created in 2025 by Hospital Clínic de Barcelona, ​​Hospital Sant Joan de Déu and the University of Barcelona, ​​a member of Catalonia.health, promotes the transfer to clinical practice of a disruptive technology aimed at improving survival and reducing the sequelae of extremely premature babies.

WIVI Vision, member of Catalonia.health, has achieved Class IIa health product certification for its visual therapy technology and has been selected by ACCIÓ as one of the ten companies in the Catalonia Exponential Leaders 2026 program.

The technology company IMAGINAE, a member of Catalonia.health, will participate as a technology partner in the NAIVE (Neotropical AI-assisted Vertebrate identification through ZooMS) project led by ICTA-UAB and scientifically directed by Dr. André Carlo Colonese, director of research at the Department of Prehistory and ICTA-UAB.

The HIPRA group, member of Catalonia.health, closed the 2025 financial year with a turnover of 516 million euros and a net profit of 53.9 million euros. The turnover represents an increase of 17% compared to the previous year and represents the highest annual turnover achieved by the group to date, consolidating its trajectory of growth and international expansion.

The Germans Trias i Pujol Research Institute (IGTP), member of Catalonia.health, celebrated on June 18 a new edition of the Innomed Awards, a day aimed at promoting biomedical innovation projects and strengthening the connection between research, the health system, entrepreneurship and investment. The event took place in the auditorium of the Josep Carreras Institute (IJC) on the Can Ruti Campus and brought together professionals from research, health, entrepreneurship and investment.

Catalonia.health member biotech company OneChain Immunotherapeutics has announced promising interim results from its ongoing clinical trial with OC-1, its CAR-T therapy, in patients with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LL), a rare and aggressive blood cancer that affects both children and adults. The data were presented on June 17 at the 2026 Congress of the European Hematology Association (EHA).